Company Description
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally.
The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.
It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
| Country | United States |
| Founded | 1987 |
| IPO Date | Dec 5, 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 952 |
| CEO | John Jacobs |
Contact Details
Address: 700 Quince Orchard Road Gaithersburg, Maryland 20878 United States | |
| Phone | 240 268 2000 |
| Website | novavax.com |
Stock Details
| Ticker Symbol | NVAX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001000694 |
| CUSIP Number | 670002401 |
| ISIN Number | US6700024010 |
| Employer ID | 22-2816046 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| John Charles Jacobs M.B.A. | President, Chief Executive Officer and Director |
| John Joseph Trizzino B.S., M.B.A. | President and Chief Operating Officer |
| James Patrick Kelly C.F.A. | Executive Vice President, Chief Financial Officer and Treasurer |
| Mark J. Casey | Executive Vice President, Chief Legal Officer and Corporate Secretary |
| Elaine O'Hara | Executive Vice President and Chief Strategy Officer |
| Richard P. Crowley | Executive Vice President and Chief Operating Officer |
| Troy Morgan Esq., J.D. | Senior Vice President, Deputy General Counsel and Chief Compliance Officer |
| Erika S. Trahan | Associate Director of Investor and Public Relations |
| Ian J. Watkins | Executive Vice President and Chief Human Resources Officer |
| Silvia Taylor M.B.A. | Executive Vice President and Chief Corporate Affairs and Advocacy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2025 | 8-K | Current Report |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 5, 2025 | 8-K | Current Report |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2025 | 8-K | Current Report |
| Apr 23, 2025 | 8-K | Current Report |
| Apr 14, 2025 | 144 | Filing |
| Apr 2, 2025 | 8-K | Current Report |